by MASA | Apr 15, 2026 | Asthma, Drug Updates, News, Severe Asthma, Type 2 Inflammation
In an interview on The Valder Beebe Show, Dr. Siri discusses the clinical and patient experience aspects of severe asthma. Over two millions Americans of various ages live with severe asthma out of 20-30 million people with asthma. From 0:30 to 3:55, Dr. Siri...
by MASA | Apr 5, 2026 | immunology, Infusion center, News, patient advocacy
In a recent op-ed for the Springfield State Journal-Register “A drug affordability board would hurt Illinois patients”, Dr. Dareen D. Siri shares a critical perspective on the proposed Prescription Drug Affordability Boards (PDABs) in Illinois. While the...
by MASA | Mar 10, 2025 | Immunodeficiency Hypogammaglobulinemia, News, Rare Diseases
Deadline: March 21, 2025 Download CIIC Patient Scholarship Application 2025 : You can submit your application to your provider. CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud...
by MASA | Dec 19, 2024 | Drug Updates
The U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, for the treatment of mild, moderate, or severe atopic dermatitis (AD) in adults and children aged 2 years and older. This approval expands the use of VTAMA, previously approved for...
by MASA | Aug 15, 2024 | Drug Updates, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jul 31, 2024 | Drug Updates
The FDA approved Zoryve cream (0.15%) for mild to moderate atopic dermatitis this year for adults and children aged above 6 years old. Roflumilast cream (marketed under the name Zoryve) is a non-steroidal topical cream that is applied once daily to affected areas of...
